May 29, 2026

To, National Stock Exchange of India Limited, "Exchange Plaza", 5th Floor, Plot No. C/1, G Block, Bandra- Kurla Complex Bandra (East), Mumbai – 400 051	To, BSE Limited, Corporate Relationship Department, 2nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400 001
Scrip Name: GLENMARK	Scrip Code: 532296
ISIN: INE935A01035	ISIN: INE935A01035
Our Reference No. 17/26-27	Our Reference No. 17/26-27

Dear Sir/ Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Investor Presentation – Q4 FY 25-26.

You are requested to take the same on record.

Thanking You.

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2026.05.29 22:17:02 +05'30'

Harish Kuber
Company Secretary & Compliance Officer

Encl: As above

glenmark
A new way for a new world

Investor Presentation
Q4 FY26

29 May 2026

Disclaimer

This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company's or its affiliates' objectives, projections and estimates are forward looking statements. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", "believes", "estimates", "expects", "intends", "plans", "predicts", "projects", "aspirations", "goals", "aim", "targets", "promises" and similar expressions.

These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements, depending upon, without limitation:

- General economic and political conditions in our key markets, government policies and other incidental factors;
- Changes in the overall macro-economic parameters including changes in the currency and interest rates either in India and / or globally;
- Ability to successfully implement our strategic plan, including research and development efforts;
- Changes in laws and regulations that apply to the pharmaceutical industry and its suppliers and customers; and
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry

Actual outcomes may vary materially from those indicated in the applicable forward-looking statements, should one or more of such risks and uncertainties materialize. No representation or warranty, either expressed or implied, is provided in relation to this presentation. This presentation should not be regarded by recipients as a substitute for the exercise of their own judgment. The Company undertakes no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Certain information in this document is not audited or reviewed by an auditor or based on Indian Accounting Standards or internationally accepted accounting principles. The reader should not consider such items as an alternative to the audited financial results or other indicators of the Company's profit, cash flows or financial performance based on applicable accounting standards.

Summary – Q4 FY26

Consolidated Revenue

- Consolidated Revenue of Rs. 37,706 million
- YoY growth of 15.8%

Regional Highlights

- India business growth of 8.2%
- North America core business growth of 7.8%
- EU business growth of 21.4%
- EM business growth of 13.7%

Profitability

- EBITDA at Rs. 7,626 million
- EBITDA margin of 20.2%
- PAT at Rs. 3,013 million with PAT margin of 7.6%

"FY26 has been a defining year in Glenmark's evolution. We delivered strong business performance while making meaningful progress against the strategic priorities that will shape our future. The landmark AbbVie partnership validated the strength of our innovation capabilities and the global relevance of our science. During the year, we expanded our portfolio of differentiated products including the successful launches of key generic respiratory products in the US which demonstrates continued expertise in our core therapeutic areas. We also accelerated the global momentum of RYALTRIS® and our collaborations during FY26 reinforced our position as the partner of choice for innovative molecule launches across markets. We are building an organization that combines the scale and resilience of a global pharmaceutical business with the scientific ambition of an innovation-driven organization amidst the evolving global landscape. As we look ahead, we remain focused on disciplined execution, differentiated science, and creating greater impact for patients around the world."

Glenn Saldanha
Chairman and Managing Director
Glenmark Pharmaceuticals Ltd.

Key Highlights – FY26

IGI secured a landmark licensing deal with AbbVie for ISB 2001

USD 700 million upfront payment with potential total deal value of USD 1.925 billion, tiered double-digit royalties on net sales; Glenmark to commercialize in Emerging Markets

Accelerated Oncology business expansion in India and Emerging Markets

In-licensing of Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma

India business delivered strong outperformance in secondary sales

1.5x the IPM growth, 2nd fastest-growing company among the top 15 companies*

Multiple differentiated product launches in India

TEVIMBRA® & BRUKINSA® (Oncology), NEBZMART GFB Smartules® / Glenmark AIRZ® FB Smartules® (Respiratory), GLIPIQ® (Diabetes)

Sustained strong global momentum in RYALTRIS®

>50% growth in secondary sales in FY26, launch in China and Thailand, end-to-end commercialization in the USA

Established branded Dermatology footprint in Europe

EU marketing authorization approval and the UK launch of WINLEVI®

Strengthened generic Respiratory franchise in the USA

First generic approval of FloVent® HFA 44 mcg with CGT designation, approval of Fluticasone Propionate Nasal Spray OTC, three additional Respiratory ANDAs filings

Monroe manufacturing facility received U.S. FDA EIR with VAI classification

Enabling restart of commercial manufacturing to support future growth in injectable and institutional business

* *As per IQVIA MAT March 2026*

Consolidated Revenue – Q4 and 12M FY26

	Fourth Quarter ended March 31			Twelve Months ended March 31		
Rs. million	**FY 2026**	**FY 2025**	**YoY Growth**	**FY 2026**	**FY 2025**	**YoY Growth**
India	*10,201*	*9,430*	*8.2%*	*37,237*	*44,845*	*-17.0%*
North America #	*9,248*	*7,146*	*29.4%*	*71,390*	*30,172*	*136.6%*
Europe	*8,907*	*7,335*	*21.4%*	*31,007*	*28,463*	*8.9%*
Emerging Markets ##	*8,979*	*7,898*	*13.7%*	*29,405*	*28,138*	*4.5%*
Total	**37,335**	**31,809**	**17.4%**	**169,039**	**131,618**	**28.4%**
Other Revenue	*371*	*753*	*-50.7%*	*786*	*1,599*	*-50.8%*
Consolidated Revenue	**37,706**	**32,562**	**15.8%**	**169,825**	**133,217**	**27.5%**

Average conversion rate in 12M FY 2025-26 considered as INR 88.33 / USD 1.00

Average conversion rate in 12M FY 2024-25 considered as INR 84.54 / USD 1.00

USD figures are only indicative

 # North America revenue for Q4 FY26 and 12M FY26 includes deferred out-licensing income recognition for ISB 2001

Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC)

India

- Significant outperformance compared to IPM in terms of secondary sales
- Recorded a strong year for its Oncology business
- Continues to be top-ranked in its core therapeutic areas
- Launched GLIPIQ® (semaglutide) in both vial and pre-filled pen forms
- Continued strong growth in Glenmark Consumer Care franchise

Revenue (Rs. million)





North America

- Launched 13 new products in FY26 across oral solids, injectables, Respiratory
- First generic approval of FloVent® HFA 44 mcg with 180-day CGT exclusivity
- Fluticasone Nasal Spray [OTC] approved, three additional Respiratory ANDAs filed
- 20 injectable products commercialized through partnerships
- Initiated commercialization of RYALTRIS® in the USA
- Monroe manufacturing facility received U.S. FDA EIR with VAI classification

Revenue (Rs. million)#





 # North America revenue for Q4 FY26 and 12M FY26 includes deferred out-licensing income recognition for ISB 2001

Europe

- Strong growth in branded markets / products
- Growing western European markets – Germany, the Netherlands and Italy
- Sustained momentum in RYALTRIS® sales across the region
- WINLEVI® gained traction since its launch in the UK in Q1 FY26
- Planning to expand its commercial Respiratory portfolio in FY27

Revenue (Rs. million)





Emerging Markets

- Continued outperformance in Russia Dermatology market
- High single-digit secondary sales growth in LATAM and MEA markets during Q4
- RYALTRIS® continues to be the leading nasal spray in the region
- RYALTRIS® launched in China and Thailand in Q4 FY26; targeting Brazil launch in FY27
- Significant market share in overall Dermatology and Respiratory covered market across APAC

Revenue (Rs. million)



Global Innovative Portfolio Update

RYALTRIS®

- Commercialized in 55 markets
- Launched in China and Thailand in Q4
- Initiated commercialization in the USA
- Robust secondary sales growth of >50 in FY26

WINLEVI®

- Launched in the UK in Q1 FY26; strong uptake throughout the year
- Received MA approval in EU, launch planned in FY27

QiNHAYO™ (ENVAFOLIMAB)

- Marketing authorization applications filed in 24 countries
- Initiated early access programs or Named Patient Programs in seven markets
- Initiated a global multi-center Phase 3 study in neo-adjuvant and adjuvant NSCLC

TRASTUZUMAB REZETECAN

- First wave of MA applications to begin Q2 FY27
- BLA for Trastuzumab Rezetecan in the 2L HER2+ breast cancer indication approved in China
- BLA for HER2+ Advanced Colorectal Cancer filed

AUMOLERTINIB

- Submitted MA applications for Aumolertinib as of March 2026
- First commercial launch anticipated during the second half of FY27

Diversity of Immune Cell Engagement Across Hematologic & Solid Tumor Indications, and Autoimmune Diseases

ONCOLOGY ASSET	DESCRIPTION	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RIGHTS
ISB 2001 (ABBV-2001)	CD38 x BCMA x CD3 Trispecific T-cell engager	Multiple Myeloma						abbvie * Glenmark
ISB 2301	Multispecific immune cell activator	Solid Tumors						IGI
ISB 2302	Bispecific immune modulator	Hematologic & Solid Tumors						IGI
ISB 2501	Trispecific T-cell engager	Solid Tumors						IGI

*IGI will partner with Glenmark to develop, manufacture, and commercialize ISB 2001 in all territories outside AbbVie's licensed markets

IMMUNOLOGY ASSET	DESCRIPTION	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RIGHTS
ISB 880 (LAD191)	IL-1RAP antagonist mAb	Hidradenitis Suppurativa						almirall
Telazorlimab (ISB 830) ISB 830-X8 (STAR-0310)	OX40 antagonist mAb	Atopic Dermatitis						biocryst

Oncology Immunology

IGI - Key updates

- **ISB 2001/ABBV-2001**
  - ISB 2001/ABBV-2001 patient enrolment in Phase 1 Dose Expansion is progressing rapidly with the goal to determine an optimal RP2D regimen. Efficacy and safety data continue to remain promising and consistent with what was previously reported.

- **ISB 2301** (Multispecific immune cell activator)
  - ISB 2301 Clinical Candidate has been selected, and the program is rapidly advancing toward the clinic with IND submission intended for end of the year

- **ISB 2302** (Bispecific immune modulator) and **ISB 2501** (Trispecific T-cell engager)**,** are both in early preclinical development

- **ISB 880/LAD191** (anti-IL-1RAP antagonist)
  - Almirall's Phase 2 clinical study in Hidradenitis Suppurativa continues to advance, with ongoing patient recruitment and dosing reinforcing the program's strong operational progress.
  - Almirall plans to initiate PoC study for additional inflammatory skin disease for the anti-IL-1RAP

- **ISB 830-X8/STAR-0310** (OX40 antagonist)
  - ISB 830-X8/STAR-0310 is in development for the treatment of AD and potentially other indications.


Thank you